Anton A. Hormann

Salzburg, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

The role of non-FDG agents in PET imaging of bladder cancer.

The role of non-FDG agents in PET imaging of bladder cancer.

Journal: Seminars in nuclear medicine

Published: November 05, 2025

Optimized Automated Cassette-Based Synthesis of [68Ga]Ga-DOTATOC.

Optimized Automated Cassette-Based Synthesis of [68Ga]Ga-DOTATOC.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: August 05, 2025

Diagnostic Value of Gastrin-Releasing Peptide Receptor-Targeted PET Imaging in Oncology: A Systematic Review.

Diagnostic Value of Gastrin-Releasing Peptide Receptor-Targeted PET Imaging in Oncology: A Systematic Review.

Journal: Seminars in nuclear medicine

Published: December 09, 2024

Fibroblast Activation Protein Inhibitor (FAPI)-Radioligand PET/CT in the Assessment of Nononcological Diseases: A Narrative Review.

Fibroblast Activation Protein Inhibitor (FAPI)-Radioligand PET/CT in the Assessment of Nononcological Diseases: A Narrative Review.

Journal: ACS pharmacology & translational science

Published: November 05, 2024

Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.

Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 28, 2024

Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy.

Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy.

Journal: European journal of nuclear medicine and molecular imaging

Published: August 16, 2024

[68Ga]Ga-FAP-2286-Synthesis, Quality Control and Comparison with [18F]FDG PET/CT in a Patient with Suspected Cholangiocellular Carcinoma.

[68Ga]Ga-FAP-2286-Synthesis, Quality Control and Comparison with [18F]FDG PET/CT in a Patient with Suspected Cholangiocellular Carcinoma.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 30, 2024

Automated production of [68Ga]Ga-DOTA-exendin-4 via fractionated radionuclide generator elution on a cassette based synthesis module.

Automated production of [68Ga]Ga-DOTA-exendin-4 via fractionated radionuclide generator elution on a cassette based synthesis module.

Journal: Nuclear medicine and biology

Published: July 14, 2023

Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study.

Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study.

Journal: Pharmaceutics

Published: January 20, 2023

Effect of N-Terminal Peptide Modifications on In Vitro and In Vivo Properties of 177Lu-Labeled Peptide Analogs Targeting CCK2R.

Effect of N-Terminal Peptide Modifications on In Vitro and In Vivo Properties of 177Lu-Labeled Peptide Analogs Targeting CCK2R.

Journal: Pharmaceutics

Published: December 29, 2022

Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.

Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: December 21, 2022

Automated Synthesis of 68Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting.

Automated Synthesis of 68Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting.

Journal: Molecules (Basel, Switzerland)

Published: December 30, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026